A Conspectus Study in Treatment of COVID-19 using Monoclonal Antibodies

International Journal of Science and Research (IJSR), Journal Year: 2024, Volume and Issue: 13(5), P. 988 - 992

Published: May 5, 2024

To prevent and/or neutralise the coronavirus in infected patients, researchers are rushing to create medicines based on antibodies. The promise for understanding disease pathophysiology was initially provided by virus's genetic and structural resemblance associated with severe acute respiratory syndrome (SARS-CoV). Reports of individual monoclonal antibodies against COVID-19 have been published researchers. main type biotherapeutics used passive immunotherapy combat viral infection is In treatment numerous diseases, therapeutic potential has long acknowledged. Neutralising interaction between spike ACE 2 receptor, which present a variety cell types, from causing infection. creation novel treatments oncology, inflammation, rare diseases as well infectious will likely be significantly impacted using manufacturing, control, chemistry methodologies because they new standard rapidity, safety, clinical advantage. Additional investigation into pathogenesis may help pinpoint best targets targeted antivirals this recently discovered disease. This brief review addressed number MABs, including an overview SARS-CoV-2 immunological response, details structure protein virus, primary target MABs' mechanisms action, comparisons successful vaccines, update trials MABs.

Language: Английский

---

Exploring the Chronic Nature of Generalized Pustular Psoriasis [Podcast]

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2024, Volume and Issue: Volume 17, P. 2487 - 2493

Published: Nov. 1, 2024

Abstract: Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterized by persistent symptoms and sudden flares of painful, sterile pustules, may be accompanied systemic inflammation. Ongoing GPP can have serious impact on patient quality life, morbidity, mortality, severe life-threatening if left untreated. Guidelines been developed for the treatment flares; however, health care professionals patients are lacking guidance management long-term, GPP. Spesolimab only FDA-approved approved use in adults pediatric aged 12 years or older weighing at least 40 kg. recently gained FDA approval as subcutaneous injection to treat when not experiencing flare. In this podcast episode, we discuss what known about chronic burden how affect life We address need guidelines results EFFISAYIL ® 2 clinical trial, which led formulation spesolimab Finally, done improve with GPP, both while flare, living symptoms. Keywords: generalized psoriasis, rare disease, spesolimab, expert opinion

Language: Английский

---

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

Dermatology Reports, Journal Year: 2023, Volume and Issue: unknown

Published: June 6, 2023

The development of flares or new-onset immune-mediated dermatologic diseases, including psoriasis, has occurred with the worldwide spreading COVID-19 pandemic. We report case a 38-year-old woman who came to our department severe flare plaque psoriasis four weeks after SARS-CoV-2 infection. Her Psoriasis Area Severity Index was 25, and her Dermatology Life Quality 18. Our initial decision prescribe acitretin, but patients reported adverse events. For this reason, we started risankizumab complete skin clearance 16 weeks. patient is still on treatment, no events have been date.

Language: Английский

---

Knowledge Mapping and Research Hotspots of Generalized Pustular Psoriasis: A Bibliometric Analysis from 2003 to 2023

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 3629 - 3643

Published: Dec. 1, 2023

Generalised pustular psoriasis (GPP) is a chronic inflammatory skin disease. We aimed to visualize the research hotspots and trends of GPP using bibliometric analysis enhance our comprehension future advancements in both basic science clinical research.Relevant publications from July 2003 2023 were obtained Web Science Core Collection on 12, 2023. The countries, institutions, authors, references, keywords associated with this subject was conducted through utilisation CiteSpace 6.2.R4, VOSviewer 1.6.18, Microsoft Excel 2019.A total 578 papers analyzed, authored by 2758 researchers 191 countries/regions 1868 published 174 academic journals. There an overall upward trajectory volume annual publications, accompanied gradual intensification interest GPP. United States, UDICE-French Research Universities, Akiyama M Nagoya University most productive influential country, institution, author, respectively. Journal Dermatology ranked first highest American Academy received citations. High-frequency included "generalized psoriasis", "psoriasis, interleukin-36", "plaque "skin-disease", "antagonist deficiency". Recent focuses have "safety", "secukinumab", "spesolimab", "ap1s3 mutations", "interleukin-36". Burst detection showed that "moderate", "ixekizumab treatment", "mutations", "efficacy", "safety" are current frontiers field.This delineated landmark defined development trends, notably applications, efficacy, safety biological agents. Future endeavors warranted explore other therapeutic options for acute long-term management

Language: Английский

---

New-Onset and Exacerbation of Psoriasis following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series

Indian Journal of Dermatology, Journal Year: 2023, Volume and Issue: 68(6), P. 724 - 724

Published: Nov. 1, 2023

Abstract Introduction: Although uncommon, several cases of new-onset and exacerbation psoriasis have been reported after coronavirus disease 2019 (COVID-19) vaccination. This study aims to systematically review reports regarding identify features related that condition following COVID-19 Materials Methods: Three databases were utilised, namely, PubMed, Google Scholar, EBSCOHost search for literature published until June 2022. We used the MeSH terms: “psoriasis,” “exacerbation,” “induced psoriasis,” “COVID-19 vaccination.” The included must report case/(s) in previously-in-remission or induced individuals receiving any dose vaccines regardless type. Results: Among 33 selected studies, an overall mean age was 57.52 ± 15.92 years. Female ( n = 40; 54.8%) more frequently than male 33; 45.2%). In terms vaccine types, Pfizer is most commonly (49 cases; 67.1%), followed by Astra-Zeneca (13 17.8%), Moderna (10 13.7%), CoronaVac (1 case; 1.4%). onset Vaccines varied, ranging from 1 90 days (Mean SD: 15.75 18.22). Plaque reported, pustular, guttate other types psoriasis. Reported treated with topical steroids monoclonal antibodies monotherapy. Conclusions: vaccination quite scarce, possibility occurrence should be acknowledged managed properly; patients informed, particularly ones history without discouraging take vaccine.

Language: Английский

---